Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence Results From the CHARM Echocardiographic Substudy–CHARMES by Persson, Hans et al.
A
f
f
(
F
D
I
M
H
U
K
b
a
Journal of the American College of Cardiology Vol. 49, No. 6, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PDiastolic Dysfunction in Heart Failure With
Preserved Systolic Function: Need for Objective Evidence
Results From the CHARM Echocardiographic Substudy–CHARMES
Hans Persson, MD, PHD,* Eva Lonn, MD, MSC,† Magnus Edner, MD, PHD,*
Lawrence Baruch, MD,‡ Chim C. Lang, MD,§ John J. Morton, PHD, Jan Östergren, MD, PHD,¶
Robert S. McKelvie, MD, PHD,† for the Investigators of the CHARM Echocardiographic
Substudy–CHARMES
Stockholm, Sweden; Hamilton, Canada; Bronx, New York; and Dundee and Glasgow, United Kingdom
Objectives We tested the hypothesis that diastolic dysfunction (DD) was an important predictor of cardiovascular (CV) death or
heart failure (HF) hospitalization in a subset of patients (ejection fraction [EF]40%) in the CHARM-Preserved study.
Background More than 40% of hospitalized patients with HF have preserved systolic function (HF-PSF), suggesting that DD
may be responsible for the clinical manifestations of HF.
Methods Patients underwent Doppler echocardiographic examination that included assessment of pulmonary venous flow
or determination of plasma NT-pro-brain natriuretic peptide 14 months after randomization to candesartan or
placebo. The patients were classified into 1 of 4 diastolic function groups: normal, relaxation abnormality (mild
dysfunction), pseudonormal (moderate dysfunction), and restrictive (severe dysfunction).
Results There were 312 patients in the study, mean age was 66  11 years, EF was 50  10%, and 34% were women.
The median follow-up was 18.7 months. Diastolic dysfunction was found in 67% of classified patients (n  293),
and moderate and severe DD were identified in 44%. Moderate and severe DD had a poor outcome compared
with normal and mild DD (18% vs. 5%, p  0.01). Diastolic dysfunction, age, diabetes, previous HF, and atrial
fibrillation were univariate predictors of outcome. In multivariate analysis, moderate (hazard ratio [HR] 3.7, 95%
confidence interval [CI] 1.2 to 11.1) and severe DD (HR 5.7, 95% CI 1.4 to 24.0) remained the only independent
predictors (p  0.003).
Conclusions Objective evidence of DD was found in two-thirds of HF-PSF patients. Moderate and severe DD, which were
found in less than one-half of the patients, were important predictors of adverse outcome. The results demon-
strate the prognostic significance and need for objective evidence of DD in HF-PSF patients. (J Am Coll Cardiol
2007;49:687–94) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.062(
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unction (HF-PSF), suggesting that diastolic dysfunction
DD) may be responsible for their clinical manifestations
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ccepted August 30, 2006.1). Recent studies have indicated that patients with HF and
jection fraction (EF) 40% have relatively high mortality
nd hospitalization rates (2). Prospective data in HF-PSF
re limited with respect to the relationship among objective
easures of DD, symptoms and signs of HF, outcome, and
herapy. A major reason for the paucity of randomized
ontrolled trials in HF-PSF patients is the difficulty in
efining and measuring diastolic function. Although hemo-
ynamic data obtained by heart catheterization can be used
o measure diastolic function, the invasive nature of this
ssessment limits its applicability to most patients (3).
herefore, Doppler echocardiography is the method of
hoice in routine clinical practice to assess for DD (4).
owever, Doppler assessment of DD is complex and
equires expert interpretation. Furthermore, loading condi-
ions affect mitral inflow pulsed-wave Doppler parameters,
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tween normal and pseudonormal
diastolic function particularly
difficult. Therefore, in addition
to mitral inflow parameters, pul-
monary venous (PV) flow Dopp-
ler and changes in mitral inflow
parameters during Valsalva ma-
neuver are commonly used to
distinguish pseudonormal from
normal diastolic function.
An alternative approach to as-
sess the presence of abnormal
hemodynamics and DD is as-
sessment of plasma natriuretic
peptides (5–8). This approach
may be of greatest benefit in
distinguishing normal from
seudonormal diastolic function in HF-PSF patients but
ay be of limited value in detecting patients with relaxation
bnormalities (5).
The CHARM (Candesartan in Heart failure: Assess-
ent of Reduction in Mortality and morbidity)-Preserved
tudy (9) examined the effect of adding candesartan cilexetil
r placebo to usual therapy in symptomatic HF-PSF pa-
ients (LVEF 40%). Candesartan led to a nonsignificant
1% reduction in the primary composite outcome, but there
as a nominally significant 29% reduction in the number of
dmissions for HF. The trial offered a unique opportunity to
escribe diastolic function and its impact on prognosis in
F-PSF patients. We conducted a multicenter interna-
ional echocardiographic substudy evaluating LV diastolic
unction in a subset of HF-PSF patients participating in the
HARM-Preserved study.
im. The primary objective of the CHARM echocar-
iographic substudy (CHARMES) was to assess whether
V diastolic function was an important predictor of the
ombined outcome of cardiovascular (CV) mortality or
ospitalization for HF, the primary end point in the
HARM-Preserved trial. The secondary objectives were
) to evaluate the effects of candesartan compared to
lacebo on LV diastolic function measured at least 14
onths after enrollment and 2) to evaluate the effects of
andesartan compared to placebo on LV mass and LV
ystolic function.
tudy design. CHARMES was a prospective, randomized,
ontrolled, double-blind cross-sectional study evaluating
V diastolic function using Doppler echocardiography and
-terminal pro-brain natriuretic peptide (NT-proBNP).
he study was originally planned to be a serial echocardio-
raphic study with an extensive Doppler echocardiographic
rotocol and assessments at baseline, after 14 months, and
t study end. Because of difficulties recruiting into this
omplex study, the protocol was changed to perform a
Abbreviations
and Acronyms
CI  confidence interval
CV  cardiovascular
DD  diastolic dysfunction
EF  ejection fraction
HF  heart failure
HF-PSF  heart failure and
preserved systolic function
HR  hazard ratio
LAVI  left atrial volume
index
LV  left ventricular
NT-proBNP  N-terminal
pro-brain natriuretic peptideimplified classification of diastolic function. aethods
atients. Patients participating in the CHARM-Preserved
tudy were asked to participate in CHARMES. The inclu-
ion and exclusion criteria for CHARMES were the same as
or the main study (9) and aimed at selecting patients with
ymptoms of HF and LVEF 40%. We excluded patients
ith poor-quality echocardiograms, prosthetic mitral valves,
r greater than moderate mitral or aortic regurgitation.
easurement of diastolic function. DOPPLER ECHOCAR-
IOGRAPHY. The examination was performed while the
atient was in a period of quiet respiration. All recordings
ere performed at a high sweep speed (100 mm/s) and with
imultaneous electrocardiographic (ECG) recording and
ncluded complete M-mode, 2-dimensional, and Doppler
chocardiographic examinations, with emphasis on evalua-
ion of LV diastolic (10–12) and systolic function (13), LV
ize, and mass (13). Assessment of PV flow and E/A during
Valsalva maneuver were optional, performed only in
enters experienced in completing those assessments. A
inimum of 10 to 15 beats was recorded for all
-dimensional, M-mode, and Doppler parameters. Apical
-, 3-, and 4-chamber views were obtained in all echocar-
iographic studies. The following measurements were used
or the assessment of LV diastolic function: 1) early filling
eak velocity (E), 2) atrial filling peak velocity (A), 3) E/A
atio, 4) deceleration time (DT), 5) isovolumic relaxation
ime (IVRT), 6) a wave duration (MVa) at the AV plane,
nd 7) E/A ratio during Valsalva manuever. The following
easurements were used for the assessment of PV flow: 1)
ystolic peak velocity (S), 2) diastolic peak velocity (D), 3)
/D ratio, 4) atrial systolic reversal wave velocity (PVa), 5)
wave duration (PVa dur), and 6) difference between PVa
nd MVa duration. Left atrial volume index (LAVI) was
alculated by the biplane area-length method from apical 2-
nd 4-chamber views indexed to body surface area (13).
T-proBNP. Blood for NT-proBNP measurement was sam-
led through a venflon or butterfly needle inserted into an
ntecubital arm vein. The patients rested for 15 min (seated
r lying) before 10 ml of blood being drawn and placed in
standard EDTA tube. The blood was centrifuged within
0 min of sampling at 5°C and 2,000 rpm for 15 min. The
lasma (3 to 4 ml) was removed and frozen at 20°C in a
lastic tube labeled with the date, patient number, and site
umbers. Plasma NT-proBNP was determined using Elec-
ys proBNP sandwich immunoassay on an Elecsys 2010
Roche Diagnostics, Basel, Switzerland). The normal NT-
roBNP cutoff values were prospectively chosen according
o age and gender (14): for men 65 years 184 ng/l and
65 years old 268 ng/l and for women age 65 years
269 ng/l and 65 years 391 ng/l.
LASSIFICATION OF DIASTOLIC FUNCTION. The classifica-
ion of diastolic function was defined prospectively based on
ge-adjusted values for all echo-Doppler parameters (Table 1)
nd NT-proBNP measurements using the algorithm out-
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February 13, 2007:687–94 Diastolic Dysfunction in HF With EF >40%ined in Figure 1. Classification was as follows: 1) normal, 2)
elaxation abnormality (mild dysfunction), 3) pseudonormal
moderate dysfunction), and 4) restrictive abnormality (se-
ere dysfunction). Two investigators (H.P. and E.L.)
linded to the patients’ clinical characteristics performed
his assessment. Relaxation and restrictive abnormalities
ere assessed by mitral inflow parameters, and the classifi-
ation was based on a minimum of 2 abnormal mitral inflow
arameters pointing to the same category. To distinguish
seudonormal from normal diastolic function, one of the
ollowing measures had to be abnormal: 1) PV flow param-
ters, 2) E/A during Valsalva maneuver, or 3) plasma
T-proBNP concentration measured at the time of echo-
ardiography. In patients with atrial fibrillation, DT was
sed to classify patients as abnormal relaxation or restrictive
iastolic dysfunction, whereas S/D (15–17) or NT-proBNP
6–7) was used to classify patients as pseudonormal diastolic
ysfunction. Left atrial volume index was analyzed as an
ndependent measure and not included in the classification
f DD.
Figure 1 Classification of LV Diastolic Function
Left ventricular (LV) diastolic function categorized into 4 groups. 1) Normal: mitral
N-terminal pro-brain natriuretic peptide (NT-proBNP). 2) Abnormal relaxation: a) ear
and/or b) isovolumic relaxation time/deceleration time (IVRT/DT) longer than age-
NT-proBNP, b) abnormal pulmonary venous flow, or c) abnormal E/A–E/A during Va
shorter than age-related value. Pulmonary venous flow was considered abnormal if
velocity less than age-related value, 2) pulmonary vein a-duration longer than mitra
mal values are in Table 1.
Normal Values for Mitral and Pulmonary Vein Do
Table 1 Normal Values for Mitral and Pulmo
20–29 30–39
E/A 1.1–3.0 1.1–2.7
IVRT (ms) 50–90 50–90
DT (ms) 140–200 140–200
S/D 0.6–1.1 0.7–1.4
PVa (cm/s) 12–28 12–28
PVa  MVa (ms) 20 20
E/A  E/A Valsalva 0.5 0.5
The given ranges for variables are meant to approximate the 95% con
leaflet tips.
DT  deceleration time; E/A  early (E) mitral inflow peak/atrial (A
atrial reversal peak flow velocity; PVa  MVa  pulmonary vein at
systolic/diastolic ratio.tatistical analysis. The baseline characteristics at the time
f randomization into the CHARM-Preserved study are
resented as standard summary statistics. The prognostic
ower of the presence of DD to predict the combined end
oint of cardiovascular mortality or rehospitalization for HF
as tested by Cox regression analysis from the date of the
chocardiogram to end of follow-up. The univariate analysis
ncluded the 11 prospectively chosen variables: age, gender,
ew York Heart Association functional classification, EF
by study echocardiogram), hypertension, diabetes mellitus,
revious admission for HF (before date of echo), previous
yocardial infarction (before date of echo), atrial fibrillation
at time of echo), LAVI, and treatment allocation. Any
erm that was significant at 0.1 in the univariate analysis
as included as a potential predictor in the first multivariate
odel. In a second step, the best prognostic model was
onstructed by testing the remaining significant variable(s)
ith forced adjustment for age, gender, EF, and treatment
llocation. Chi-square tests were used to relate DD to
ackground variables. Analysis of variance was used to assess
parameters within normal range and normal pulmonary vein flow or normal
g peak velocity/atrial filling peak velocity (E/A) ratio lower than age-related value
value. 3) Pseudonormal: normal mitral inflow parameters and a) elevated
. 4) Restrictive: a) E/A ratio higher than age-related value and/or b) IVRT/DT
ne of the following criteria were present: 1) pulmonary vein systolic/diastolic
ration, or 3) pulmonary vein peak a-velocity greater than age-related value. Nor-
Flows by Age
Vein Doppler Flows by Age
Age (yrs)
–49 50–59 60–69 70–85
–2.5 0.8–1.9 0.7–1.5 0.6–1.3
–90 55–100 60–110 60–110
–200 140–220 140–220 140–260
–1.8 0.9–2.2 1.0–2.5 1.0–2.5
–28 15–30 15–30 15–30
20 20 20 20
0.5 0.5 0.5 0.5
limits for normal patients (10–12). Mitral values are for sampling at
peak ratio; IVRT  isovolumic relaxation time; PVa  pulmonary vein
ation  mitral inflow atrial duration; S/D  pulmonary vein peakinflow
ly fillin
related
lsalva
any o
l a-duppler
nary
40
0.9
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0.8
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Diastolic Dysfunction in HF With EF>40% February 13, 2007:687–94trend for difference in LAVI within the groups of DD.
he study sample size was calculated to allow the detection
f a 12% difference in DD, categorized as normal 
bnormal relaxation versus pseudonormal  restrictive pat-
ern between the 2 treatment groups (for alpha  0.05 and
0% power and using the chi-square test). Mitral inflow
ata, LV mass, EF, and LV end-systolic and -diastolic
iameters were compared between treatment groups. For
ontinuous variables, the difference in means, 95% confi-
ence intervals, and the t test p value are reported. Survival
urves were estimated using the Kaplan-Meier method, and
ifferences were assessed using the log-rank test. Statistical
nalysis System (SAS), proprietary software release 8.2
SAS Institute Inc., Cary, North Carolina), was used for the
nalysis.
tudy organization. All investigators participating in the
HARM-Preserved study were invited to participate in the
HARMES substudy. Danderyd University Hospital and
amilton Health Sciences were the core laboratories, re-
ponsible for the protocol, training of sites, and reading
tudy echocardiograms. A training tape and an echocardio-
raphic study manual were sent to the respective sites, and
recorded test echocardiogram was reviewed at one of the
ore laboratories. Sites were approved if the quality of the
Baseline Characteristics
Table 2 Baseline Characteristics
Variable Group
Age (yrs) Mean 
Gender Female
Ethnicity European
Smoking Non-smo
Heart rate (beats/min) Mean 
Systolic BP (mm Hg) Mean 
Diastolic BP (mm Hg) Mean 
BMI (kg/m2) Mean 
Ejection fraction (%) Mean 
New York Heart Association functional class
II
III
IV
Previous hospitalization for heart failure
Previous myocardial infarction
Angina pectoris
Hypertension
Diabetes mellitus
Atrial fibrillation
ECG: atrial fibrillation/flutter
Digitalis glycoside
Diuretics
Spironolactone
Beta-blocker
Calcium-channel blocker
Oral anticoagulant
Acetylsalicylic acid
ACE inhibitorACE  angiotensin-converting enzyme; BMI  body mass index; BP  bloodest echocardiogram was good. Forty-eight sites participated
n the study. Echocardiograms were recorded at the investiga-
or’s site and shipped to one of the core laboratories, with a
ingle reader at each site. Inter-reader variability for 10 diastolic
unction measurements was assessed in 25 patients between the
laboratories using intra-class correlation coefficients (median
ntra-class correlation coefficients 0.784, range 0.667 to 0.954).
ll NT-proBNP measurements were performed at the West-
rn Infirmary, Glasgow, Scotland.
thical considerations. The echocardiographic substudy
as approved by the ethical review boards of Karolinska
nstitutet, Stockholm, Sweden; the Hamilton Health Sci-
nces, Hamilton, Canada; and the ethical committees in the
espective centers participating in the substudy. The study
as conducted according to the rules outlined in the
elsinki declaration.
esults
tudy sample. A total of 312 patients, representing 10% of
he patients in the CHARM-Preserved study (9), were
ncluded in the CHARMES substudy. The baseline charac-
eristics of the patients in the substudy are shown (Table 2).
ompared with the main trial, CHARMES patients were
Candesartan
(n  166)
Placebo
(n  146)
Total
(n  312)
66 11 66 11 66 11
57 (34%) 49 (34%) 106 (34%)
141 (85%) 131 (90%) 272 (87%)
50 (30%) 41 (28%) 91 (29%)
68.9 10.9 67.0 12.0 68.0 11.5
133.7 19.4 135.7 18.7 134.7 19.1
76.8 11.4 76.2 10.5 76.5 11.0
30.1 6.7 29.0 5.3 29.6 6.1
50 10 50 10 50 10
87 (52%) 89 (61%) 176 (56%)
75 (45%) 54 (37%) 129 (41%)
4 (2.4%) 3 (2.1%) 7 (2.2%)
103 (62%) 75 (51%) 178 (57%)
83 (50%) 72 (49%) 155 (50%)
103 (62%) 93 (64%) 196 (63%)
109 (66%) 102 (70%) 211 (68%)
56 (34%) 45 (31%) 101 (32%)
53 (32%) 40 (27%) 93 (30%)
20 (12%) 15 (10%) 35 (11%)
51 (31%) 30 (21%) 81 (26%)
123 (74%) 108 (74%) 231 (74%)
19 (11%) 7 (5%) 26 (8%)
99 (60%) 86 (59%) 185 (59%)
50 (30%) 53 (33%) 103 (33%)
37 (22%) 37 (25%) 74 (24%)
106 (64%) 93 (64%) 199 (64%)
38 (23%) 31 (21%) 69 (22%)SD
ker
SD
SD
SD
SD
SDpressure; ECG  electrocardiogram.
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February 13, 2007:687–94 Diastolic Dysfunction in HF With EF >40%ess often women (34% vs. 40%) and had a less frequent
57% vs. 69%) history of admission for HF. The 2 treatment
roups in the CHARMES substudy were well balanced
egarding age, gender, EF, and other variables.
ystolic function. Echocardiograms were performed 17.7
onths (median) after randomization. The LVEF mea-
ured at14 months into the study was35% in 12% (n
9) of patients, in contrast to the baseline LVEF that was
40% in all patients as defined by CHARM-Preserved
tudy criteria.
iastolic function. A total of 293 patients (94%) could be
lassified according to the protocol. In the patients with
ormal mitral inflow, NT-proBNP was used in 86% of
atients (n  178) to distinguish pseudonormal patients
rom normal patients, whereas Doppler measurements were
sed in the remaining 14% (n  29). Diastolic dysfunction
as found in 67% (n  197) of all patients, similar to the
4% (n  27) of the 42 patients who were assessed at
aseline. Moderate dysfunction was the most common abnor-
ality, whereas severe DD was relatively rare (Table 3).
iastolic dysfunction was related to a number of baseline
haracteristics, including higher age (p  0.01), worse New
ork Heart Association functional class (p  0.05), previ-
us admission for HF (p  0.01), and atrial fibrillation by
istory or ECG (p  0.001); hypertension, EF, and
Figure 2 CV Death or HF Hospitalization
According to Diastolic Function Class
Univariate hazard ratios (95% confidence intervals) for relaxation abnormality
versus normal  1.4 (0.4 to 5.7); pseudonormal versus normal  4.5 (1.5 to
13.2); and restrictive versus normal  7.2 (1.8 to 29.0). CV  cardiovascular;
HF  heart failure.
Diastolic Function in All Patients and Left AtrialVolume Index by D astolic Function Class
Table 3 Diastolic Function in All Patients anVolume Index by Diastolic Function
Normal Mild
n (%) 98 (33) 65 (22)
LAVI (ml/m2) 36 11 39 16
LAVI  left atrial volume index.iabetes mellitus were not associated with DD. Left atrial
olume index was abnormal (32 ml/m2) in 71% of the
atients and showed a powerful relation to severity of DD
Table 3).
rognosis. The median follow-up time was 18.7 months
fter the echocardiogram. Cardiovascular mortality or re-
ospitalization for HF during follow-up was 10.3% (n 
2), with a CV mortality of 4.5% (n  14). The combined
nd point of CV death or hospitalization for HF was related
o the severity of DD (p  0.0015) (Fig. 2), but not to
AVI (p  0.13). Similar hazard ratios as those reported in
igure 2 for the 3 groups of DD versus normal were found
n patients without atrial fibrillation (1.6, p 0.48; 3.6, p
.03; and 8.4, p  0.01) and excluding patients with EF
35% (1.1, p  0.94; 3.2, p  0.04; and 6.5, p  0.01).
atients with normal diastolic function had a low event rate
5%). Patients with a relaxation abnormality had a non-
ignificantly higher event rate than normal patients (6%),
hereas patients with moderate and severe DD had signif-
cantly higher event rates (16% and 29%, respectively).
atients with pseudonormal DD diagnosed by abnormal
T-proBNP or Doppler criteria had similar outcomes (Fig.
). Higher age, diabetes mellitus, previous HF admission,
nd atrial fibrillation were all significantly related to worse
utcome (p  0.05) (Table 4). In the multivariate analysis,
Figure 3 CV Death or HF Hospitalization in Group
With Pseudonormal Diastolic Function
Univariate hazard ratio (95% confidence intervals) for outcome in patients with
pseudonormal diastolic dysfunction characterized by N-terminal pro-brain natri-
uretic peptide (NT-proBNP) versus Doppler  0.8 (0.2 to 2.7). Abbreviations as
in Figure 2.
ft Atrial
s
Moderate Severe p Value
109 (37) 21 (7)
46 16 55 23 0.00001d Le
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Diastolic Dysfunction in HF With EF>40% February 13, 2007:687–94nly moderate and severe DD remained significantly related
o outcome. This relationship persisted after adjusting for
ge, gender, EF at time of echo, and treatment allocation.
ifferences by treatment group. There were no significant
ifferences in LV diastolic and systolic function or size
etween the placebo and candesartan groups (Table 5);
here was a similar distribution of DD class in both
reatment groups (p  0.85). Of note, candesartan treated
atients had lower LV mass and LV mass index (p  0.05).
ewer patients on candesartan had LV hypertrophy (45%
s. 59%, p  0.04), defined as 116 g/m2 for men and 104
/m2 for women (18).
iscussion
e have identified DD in 67% of the patients with
F-PSF. Significant DD, classified as moderate to severe,
hich was found in fewer than one-half of the patients, was
n important independent predictor of adverse outcome.
nivariate and Multivariate Analyses of Factors Related to CV Dea
Table 4 Univariate and Multivariate Analyses of Factors Relate
Univariate HR
(95% CI) p Value
Diastolic dysfunction (moderate/severe vs.
normal/mild)
4.13 (1.85–9.24) 0.001
Age 1.04 (1.01–1.08) 0.023
Diabetes 2.13 (1.06–4.26) 0.033
Previous HF admission 2.24 (1.04–4.90) 0.040
Atrial fibrillation 2.17 (1.03–4.59) 0.042
LA volume index 1.02 (0.99–1.04) 0.127
NYHA III vs. II 1.70 (0.84–3.44) 0.139
EF 1.02 (0.98–1.07) 0.200
Male gender 1.65 (0.74–3.68) 0.218
Previous MI 1.36 (0.67–2.45) 0.398
NYHA IV vs. II 1.90 (0.25–14.37) 0.535
Treatment allocation C vs. placebo 1.19 (0.59–2.39) 0.627
Hypertension 1.05 (0.51–2.18) 0.894
One p value for mild-severe diastolic dysfunction versus normal diastolic function.
C  candesartan; CI  confidence interval; ECG  electrocardiography; EF  ejection fraction;
YHA  New York Heart Association.
LV Size, Mass, Systolic, and Diastolic Function
Table 5 LV Size, Mass, Systolic, and Diasto
Candesartan Placebo
E/A 1.15 0.84 1.10 0.60
IVRT (ms) 99 23 98 22
DT (ms) 215 57 213 63
LV mass (g) 225 75 250 109
LVMI (g/m2) 111 35 124 49
LVEDD (mm) 54 7 55 9
LVESD (mm) 36 7 37 10
EF (%) 48 11 49 10
50 (20–65) 50 (15–65)
Mean  SD are presented for all variables. Mean  SD and median (
LV left ventricular; LVEDD left ventricular end-diastolic diameter; LVESD
index; other abbreviations as in Table 1.his was in contrast to lower EF, which was not related to
utcome in patients with HF-PSF. Furthermore, we have
ound that DD was related to measures of disease severity,
trial fibrillation, LAVI, and higher age. The lower LV
ass in candesartan-treated patients suggests a treatment
ffect by candesartan compared to placebo.
iastolic dysfunction and prognosis. In population stud-
es, mild, moderate, or severe DD is related to long-term
ortality compared with normal patients (4). Our findings
f a favorable intermediate-term prognosis in patients
ith mild DD might seem in conflict with previous
tudies. Most likely, this discrepancy results from the
onger duration of follow-up in the population studies.
ur findings support only a weak link between echocar-
iographically determined relaxation abnormality and
F; however, this does not exclude its role as a predictor
f long-term mortality. Moderate and severe DD were
he strongest predictors of adverse outcomes in our study,
onfirming previous population-based studies, which
HF Hospitalization
CV Death or HF Hospitalization
Multivariate HR
(95% CI) p Value
iastolic dysfunction (moderate/severe vs.
normal/mild)
3.27 (1.41–7.56) 0.003
ge 1.03 (0.99–1.07) 0.205
ale gender 1.58 (0.69–3.66) 0.261
F 1.02 (0.98–1.06) 0.331
reatment allocation 1.40 (0.67–2.92) 0.372
iastolic dysfunction (mild vs. normal) 1.49 (0.37–6.00) *
iastolic dysfunction (moderate vs. normal) 3.69 (1.23–11.11) 0.023*
iastolic dysfunction (severe vs. normal) 5.72 (1.36–23.99) *
ge 1.02 (0.98–1.06) 0.238
ale gender 1.62 (0.71–3.71) 0.248
F 1.02 (0.98–1.06) 0.288
reatment allocation 1.39 (0.67–2.90) 0.390
eart failure; HR  hazard ratio; LA  left atrial; LV  left ventricular; MI  myocardial infarction;
eatment Allocation
nction by Treatment Allocation
Difference
of Means
95% Confidence
Interval p Value
0.05 0.13–0.24 0.56
0.50 4.87–5.87 0.85
1.51 11.9–14.9 0.83
25 49–1.8 0.04
13 24–1.5 0.02
1.1 3.1–0.8 0.26
0.8 3.0–1.4 0.49
1.50 3.95–0.94 0.23
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utcomes, especially HF.
The absence of objective criteria of DD in 33% of study
atients at 14 months after randomization may reflect an
mprovement in diastolic function over the course of the
rial. However, given that we found normal diastolic func-
ion in a similar proportion (36%) of patients who under-
ent assessment of DD at baseline, it appears likely that
bout one-third of patients randomized in the study did not
ave objective evidence for DD at study entry. These
ndings highlight the difficulty associated with establishing
diagnosis of DD on the basis of clinical criteria alone and
ay explain the better than expected prognosis in the
HARM-Preserved study.
revalence of diastolic dysfunction. The prevalence and
ole of DD in patients with HF-PSF is unclear. We report
6-fold higher prevalence of moderate-to-severe DD (44%)
n HF-PSF compared with the 7% prevalence of moderate-
o-severe isolated DD in the community-based study of
edfield et al. (4). The event rate was high in these patients.
hus, our prognostic results suggest that moderate and
evere DD is an important pathophysiologic mechanism in
F-PSF (3), more important than atrial fibrillation, LVEF,
r LAVI. Transient or mild systolic dysfunction has been
uggested to be the mechanism for HF in HF-PSF (19),
lthough this has been disputed (3,20). Misdiagnosis of
resumed HF is a common explanation for symptoms due
o noncardiac disease or ischemia, especially if objective
riteria of LV systolic and diastolic dysfunction are not
ncluded for diagnosis (21). The CHARM-Preserved study
ay thus be biased by inclusion of misdiagnosed patients
ithout HF, so careful objective entry criteria need to be
ought in future trials of HF-PSF.
iastolic dysfunction and relation to background factors.
trial fibrillation and LAVI were the strongest background
actors related to DD (4,22). The relationship between
trial fibrillation and more severe DD was strong whether
trial fibrillation was defined by ECG (low prevalence) or by
istory (high prevalence), suggesting that it is not simply
ecause of the difficulties in measuring DD in patients in
trial fibrillation. In our study, age was an important factor
ven after using age-adjusted normal values, pointing to a
trong link between DD and age. Systolic dysfunction by
F was not related to the degree of DD. Others (4,23) have
ound a relation between severe DD and severe systolic
ysfunction. Our patients were defined by showing no or
orderline systolic dysfunction at study entry, thus reducing
he chance to confirm this relation. We found no relation-
hip between DD and diabetes mellitus, hypertension, or
V hypertrophy by ECG, which is surprising and contrasts
ith other reports (24,25).
ethodology for diagnosis of diastolic dysfunction. Our
efinition of diastolic function reflects diastolic filling rather
han intrinsic parameters of diastolic function. Although
oppler echocardiography plays a pivotal role in assessinghe diastolic filling dynamics of the LV, this technique is iimited by the confounding influences of changes in heart
ate and loading conditions. These limitations suggest the
eed for other objective measures of DD. In this regard,
ecent studies support the value of BNP determination in
he evaluation of LV diastolic function. The release of BNP
as been shown to be directly proportional to pressure
verload (6,7), and several studies have shown that elevated
NP levels accurately predict the presence of DD seen with
oth Doppler velocity recordings (8,23,26–28) as well as
ith tissue Doppler imaging (29). Indeed, these findings
uggest that in patients with normal systolic function, either
levated BNP or echocardiographic diastolic filling abnor-
alities might help to reinforce the diagnosis of DD
8,28,29). The increase of LAVI by severity of DD supports
he diagnostic model we have used. Left atrial volume index
id not predict outcome, which may be related to low
ower. However, DD may be the underlying mechanism,
nd increase of LAVI the consequence. This interpretation
s supported by others (22), who found that DD, but not
AVI, was of prognostic importance in multivariate analy-
is. More novel echo-Doppler approaches, including tissue
oppler and color M-mode, may be more accurate in
dentifying and classifying DD; however, these techniques
ere not widely available and standardized at the time the
tudy was done.
reatment effects of angiotensin-receptor blockers in
F-PSF. We found no difference in LV size or systolic or
iastolic function for candesartan compared to placebo. The
bserved differences in LV mass are interesting and suggest
treatment effect by candesartan, but are of low evidence
rade owing to the lack of baseline data. The findings are
onsistent with other studies using angiotensin-receptor
lockers in general and candesartan specifically (18,30).
tudy limitations. There are several limitations to our
tudy. The most important ones are 1) the difficulties in
easuring diastolic function in an international multicenter
etting, 2) the difficulties measuring diastolic and systolic
unction in atrial fibrillation, 3) the absence of tissue
oppler imaging, 4) the use of NT-proBNP as a tool for
ssessing DD, and 5) the cross-sectional design of the study.
However, our protocol has a number of strengths, includ-
ng its prospective nature, use of age-adjusted values, and
ssessment of left atrial volume and EF. In addition, we
ere able to obtain good standardization, most studies sent
y the centers were of adequate quality for evaluation, and
here was good agreement among the core labs. Most
mportantly, DD as identified in our study was a very potent
redictor of outcomes.
The issue of DD in atrial fibrillation is complex, but our
esults were similar when patients with atrial fibrillation
ere excluded. The similar outcome for pseudonormal
atients diagnosed by Doppler or NT-proBNP argues for
he use of NT-proBNP when there are difficulties in
erforming a more complex echocardiogram.
mplications. Our results show the predictive value of DD
n HF-PSF, which demonstrates the need to obtain objec-
t
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Diastolic Dysfunction in HF With EF>40% February 13, 2007:687–94ive evidence of abnormal diastolic filling in patients with
F-PSF. We could identify patients at elevated risk who
re likely to benefit from HF treatments. Furthermore, in
ow-risk patients, misdiagnosis and unnecessary treatment
an be avoided. Our findings support current guidelines for
atients with suspected HF, which emphasize the need to
how objective evidence of systolic or diastolic dysfunction.
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